BOTHELL, Wash.–(BUSINESS WIRE)–Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointment of Kinney Horn as Chief Business Officer. Mr. Horn brings to Immunome extensive experience across life sciences corporate and business development, alliance management, and commercial strategy.
“With the recent acquisition of AL102, Immunome is now a clinical stage company, and Kinney’s expertise in navigating the complex business landscape of biotechnology and his successful track record in forging strategic partnerships will be crucial as we expand our portfolio and enhance our development capabilities.”Post this
“Immunome is excited to welcome Kinney to our executive team as we advance our broad pipeline of targeted therapies,” stated Clay Siegall, PhD, President and Chief Executive Officer of Immunome. “With the recent acquisition of AL102, Immunome is now a clinical stage company, and Kinney’s expertise in navigating the complex business landscape of biotechnology and his successful track record in forging strategic partnerships will be crucial as we expand our portfolio and enhance our development capabilities.”
“I am thrilled to join Immunome at such a transformative time,” remarked Mr. Horn. “The opportunity to drive strategic business initiatives and expand Immunome’s strong portfolio is incredibly compelling. I look forward to working closely with Clay and the talented team at Immunome to make a meaningful impact on the lives of cancer patients.”
Prior to joining Immunome, Mr. Horn was Chief Business Officer of Olema Oncology. In that role, he played an integral role in raising over $300M in capital, building the company, and expanding its pipeline through strategic transactions including the collaboration with Aurigene that produced the Company’s KAT6 program. Before Olema, he was an Entrepreneur in Residence at EcoR1 Capital.
Mr. Horn spent 16 years at Genentech, identifying both preclinical and clinical stage business development opportunities, structuring strategic alliances, and negotiating deals. During his time at Genentech, Mr. Horn closed numerous transactions and managed contractual relationships representing over $30B in value. Prior to Roche’s acquisition of Genentech, Mr. Horn also worked with early-stage biotechnology companies that Genentech invested in through GenenFUND, Genentech’s private equity fund. He began his career in various investment banking and venture roles.
Mr. Horn has degrees in economics, international affairs and biochemistry from Mary Washington College and Georgetown University.
About Immunome, Inc.
Immunome is a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies. Our portfolio pursues each target with a modality appropriate to its biology, including small molecules, ADCs, RLTs and immunotherapies. We believe that pursuing underexplored targets with appropriate drug modalities leads to transformative therapies. Our proprietary memory B cell hybridoma technology allows for the rapid screening and functional characterization of novel antibodies and targets.
For more information, visit www.immunome.com or follow us on X/Twitter and LinkedIn.
Cautionary Statement Regarding Forward-Looking Statements
Certain statements contained in this communication regarding matters that are not historical facts, are forward-looking statements within the meaning of Section 21E of the Securities and Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). We use words such as “excited,” “advance,” “will,” “look forward,” “opportunity,” and similar expressions to identify these forward-looking statements that are intended to be covered by the safe-harbor provisions of the PSLRA. These forward-looking statements include, but are not limited to, statements regarding Immunome’s expectation to expand its portfolio, enhance its development capabilities and drive strategic business initiatives; Immunome’s expectation about management’s performance; and other statements regarding management’s intentions, plans, beliefs, expectations or forecasts for the future. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Such forward-looking statements are based on Immunome’s expectations and involve risks and uncertainties; consequently, actual results may differ materially from those expressed or implied in the statements due to a number of factors. These factors include, but are not limited to, the risk that Immunome will not be able to realize the benefits of its strategic transactions, Immunome’s ability to grow and successfully execute on its business plan, including the development and commercialization of its pipeline; changes in the applicable laws or regulations; the possibility that Immunome may be adversely affected by other economic, market, business, and/or competitive factors; the risk that regulatory approvals for Immunome’s programs and product candidates are not obtained, are delayed or are subject to unanticipated conditions; the risk that pre-clinical data may not be predictive of clinical data; the risk that interim results of a clinical trial do not necessarily predict final results; potential delays in the commencement, enrollment and completion of clinical trials and the reporting of data therefrom; the risk that our product and development candidates fail to achieve their intended endpoints; the complexity of numerous regulatory and legal requirements that Immunome needs to comply with to operate its business; the reliance on Immunome’s management; the prior experience and successes of the Immunome’s management team not being indicative of any future success; uncertainties related to Immunome’s capital requirements and Immunome’s expected cash runway; the failure to obtain, adequately protect, maintain or enforce Immunome’s intellectual property rights; and other risks and uncertainties indicated from time to time described in exhibit 99.2 filed with Immunome’s Current Report on Form 8-K with Securities and Exchange Commission (“SEC”) on February 13, 2024, and in Immunome’s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on March 28, 2024, and in Immunome’s other filings with the SEC. Immunome cautions that the foregoing list of factors is not exclusive and not to place undue reliance upon any forward-looking statements which speak only as of the date made. Moreover, Immunome operates in a very competitive and rapidly changing environment. New risks emerge from time to time. Except as required by law, Immunome does not undertake any obligation to update publicly any forward-looking statements for any reason after the date of this press release to conform these statements to actual results or to changes in their expectations.
Contacts
Investor Contact
Max Rosett
Interim Chief Financial Officer
[email protected]
Discover more from Impact Newswire
Subscribe to get the latest posts sent to your email.
